By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Current study results on Biotechnology have been published. According to news originating from St. Louis, Missouri, by NewsRx correspondents, research stated, "Adequate therapies are lacking for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases. The ability to use antisense oligonucleotides (ASOs) to target disease-associated genes by means of RNA may offer a potent approach for the treatment of these, and other, neurodegenerative disorders."
Our news journalists obtained a quote from the research from the Washington University School of Medicine, "In modifying the basic backbone chemistry, chemical groups, and target sequence, ASOs can act through numerous mechanisms to decrease or increase total protein levels, preferentially shift splicing patterns, and inhibit microRNAs, all at the level of the RNA molecule. Here, we discuss many of the more commonly used ASO chemistries, as well as the different mechanisms of action that can result from these specific chemical modifications. When applied to multiple neurodegenerative mouse models, ASOs that specifically target the detrimental transgenes have been shown to rescue disease associated phenotypes in vivo. These supporting mouse model data have moved the ASOs from the bench to the clinic, with two neuro-focused human clinical trials now underway and several more being proposed."
According to the news editors, the research concluded: "Although still early in development, translating ASOs into human patients for neurodegeneration appears promising."
For more information on this research see: Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics, 2013;10(3):486-97. (Elsevier - www.elsevier.com; Neurotherapeutics - www.elsevier.com/wps/product/cws_home/711525)
The news correspondents report that additional information may be obtained from S.L. DeVos, Dept. of Neurology, Washington University in St Louis School of Medicine, St Louis, MO 63110, United States (see also technology.html">Biotechnology).
Keywords for this news article include: Antisense Technology, Biotechnology, Missouri, St. Louis, United States, Bioengineering, North and Central America, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC